81593-57-9

Upstream product

• 81593-56-8 [[2-(3-Methoxy-phenyl)-ethyl]-(toluene-4-sulfonyl)-amino]-acetic acid 
• 2039-67-0 2-(3-methoxyphenyl)-1-ethanamine 
• 98-59-9 p-toluenesulfonyl chloride 
• 64880-89-3 N-[(3-methoxyphenyl)ethyl]-4′′-methylbenzenesulfonamide 

Downstream Products

• 1253197-28-2 7-benzyloxy-3-(4-tosyl)-2,3,4,5-tetrahydro-3-benzazepine-1-one 
• 1253197-50-0 (+/-)-3-(1-benzoylpiperidin-4-yl)2,3,4,5-tetrahydro-1H-3-benzazepine-1,7-diol 
• 1253197-51-1 (+/-)-3-(1-benzoylpiperidin-4-yl)-7-benzyloxy-2,3,4,5-tetrahydro-1H-3-benzazepin-1-ol 
• 1253197-48-6 (+/-)-4-(1,7-dihydroxy-2,3,4,5-tetrahydro-1H-3-benzazepin-3-yl)-1-(4-fluorophenyl)butan-1-one 
• 1253197-49-7 (+/-)-4-(7-benzyloxy-1-hydroxy-2,3,4,5-tetrahydro-1H-3-benzazepin-3-yl)-1-(4-fluorophenyl)butan-1-one 
• 1253197-47-5 (+/-)-trans-3-(4-phenylcyclohexyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-1,7-diol 
• 1253197-46-4 (+/-)-3-(3-phenoxypropyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-1,7-diol 
• 1253197-43-1 (+/-)-7-benzyloxy-3-(3-phenoxypropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-1-ol 
• 1253197-41-9 (+/-)-cis-3-(4-phenylcyclohexyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-1,7-diol 
• 1253197-40-8 (+/-)-N-benzyl-2-(1,7-dihydroxy-2,3,4,5-tetrahydro-1H-3-benzazepin-3-yl)-N-methylacetamide 
• 1253197-39-5 (+/-)-N-benzyl-2-[7-(benzyloxy)-1-hydroxy-2,3,4,5-tetrahydro-1H-3-benzazepin-3-yl]-N-methylacetamide 
• 1253197-38-4 (+/-)-WMS-1410 
• 1253197-37-3 (+/-)-7-benzyloxy-3-(1,4-dioxaspiro[4.5]decan-8-yl)-2,3,4,5-tetrahydro-1H-3-benzazepin-1-ol 
• 1257108-44-3 (+/-)-7-(benzyloxy)-3-(3-phenylbenzyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-1-ol 

Relevant academic research and scientific papers

NR2B SELECTIVE NMDA-RECEPTOR ANTAGONISTS FOR TREATMENT OF IMMUNE-MEDIATED INFLAMMATORY DISEASES

The present invention provides novel means and methods for treatment auf immunemediated inflammatory diseases.

BENZAZEPIN-1-OL-DERIVED PET LIGANDS WITH HIGH IN VIVO NMDA SPECIFICITY

The present invention is directed to benzazepin-1-ol-derived compounds for use in the diagnosis of NMDA receptor-associated diseases or disorders by positron emission tomography (PET). The invention also relates to a method for the diagnosis of NMDA-receptor-associated diseases or disorders by administering to a patient in need of such diagnosis a radioactively labelled compound of the invention in an amount effective for PET imaging of NMDA receptors, recording at least one PET scan, and diagnosing an NMDA-receptor-associated disease or disorder from an abnormal NMDA receptor expression pattern on the PET scan. NMDA-receptor-associated diseases or disorders that can be diagnosed with the radioactively labelled benzazepin-1-ol-derived compounds include but are not limited to neurodegenerative diseases or disorders, Alzheimer's disease, depressive disorders, Parkinson's disease, traumatic brain injury, stroke, migraine, alcohol withdrawal and chronic and neuropathic pain.

Design, synthesis, and biological evaluation of 3-benzazepin-1-ols as NR2B-selective NMDA receptor antagonists

Cleavage and reconstitution of a bond in the piperidine ring of ifenprodil (1) leads to 7-methoxy-2,3,4,5-tetrahydro-1H-3-benzazepin-1-ols, a novel class of NR2B-selective NMDA receptor antagonists. The secondary amine 7-methoxy-2,3,4,5-tetrahydro-1H-3-be

NR2B-SELECTIVE NMDA-RECEPTOR ANTAGONISTS

The present invention relates to compounds according to general formula (I) and pharmaceutical compositions comprising compounds according to general formula (I).